IXICO plc IXICO to Present AI Segmentation Research (3606D)

TIDMIXI

RNS Number : 3606D

IXICO plc

19 February 2020

19 February 2020

IXICO plc

("IXICO" or the "Company")

IXICO to Present AI Segmentation Research at Huntington's Disease Therapeutics Conference

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience , today announces that it is scheduled to present a scientific poster on enhancing imaging analysis accuracy for Huntington's Disease (HD) by comparing two types of Artificial Intelligence (AI) techniques at the CHDI Foundation 15 (th) Annual 2020 Huntington's Disease Therapeutics Conference held from 24 - 27 February, 2020 in Palm Springs, California, USA.

Further details of the presentation are as follows:

Title: Fully automatic AI segmentation of subcortical regions: comparison of ATLAS and deep-learning based approaches

Wednesday, 26th February, Group B: Human Studies at 2.30 - 4pm, Poster number 101

Authors: Kirsi M Kinnunen (1*,) Jack Weatheritt (1) , Richard Joules (1) , Robin Wolz (1,2)

Changes in the volume of the caudate and putamen regions are used as biomarkers to track the development of Huntington's disease and monitor the potential effect of interventional treatments. Accurate volume calculations, obtained via segmentations, are therefore of utmost clinical importance. This poster compares and contrasts two AI approaches for anatomical segmentation - the first is an established atlas-based manifold learning technique, IXICO's proprietary LEAP technology; the second is a deep-learning model based on a 3D convolutional neural network (CNN).

Dr Robin Wolz, Senior Vice President, Science & Innovation at IXICO commented: "Huntington's Disease continues to be a focus for IXICO in its efforts to provide pioneering technologies to support the advancement of effective treatments for rare neurological diseases. Our research in imaging analytics will provide an insight into the best methods for monitoring both the progression of the disease as well as the potential effect of interventional treatments."

1) IXICO plc, London, UK 2) Imperial College London, London, UK. *Presenting author.

IXICO will be attending /presenting at upcoming conferences:

Neurodegenerative Drug Development Summit : 25-27 February 2020, Hyatt Regency Boston, Boston, USA

ARCA Global Conference : 2-3 March 2020, Sheraton Denver Downtown, Denver, USA

IXICO will be presenting at the conference.

The Wearable Technology Show : 10-11 March 2020, The Business Design Centre, London, UK

ADPD Focus Meeting : 2-5 April 2020, Austria Center, Vienna, Austria

SCA Global Conference : 6-7 April 2020: German Center for Neurodegenerative Diseases, Bonn, Germany

IXICO will be presenting and co-sponsoring the event.

BioTrinity 2020 : 28-29 April 2020, etc.venues, 155 Bishopsgate , London, UK

   17 (th) Annual Anglonordic Life Science Conference:   23-24 June 2020, County Hall, London, UK 

For further information please contact:

 
 IXICO plc                                     [phone] 
 Alison Howie, Chief Product Officer 
 
 Optimum Strategic Communications               [phone] 
 Mary Clark / Supriya Mathur / Manel Mateus 
 [e-mail] 
 

About IXICO

IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience.

Our goal is to be a leading proponent in the use of Artificial Intelligence (AI) in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.

More information is available on www.IXICO.com

About CHDI Foundation

CHDI Foundation is a privately-funded, not-for-profit biomedical research organization devoted to a single disease - Huntington's disease (HD). The foundation's mission is to develop drugs that will slow the progression of Huntington's disease and provide meaningful clinical benefit to patients as quickly as possible. To achieve this CHDI manages a diverse portfolio of research projects through a novel virtual model that encourages scientific collaboration to more directly connect academic research, drug discovery and clinical development. This helps bridge the translational gap that often exists between academic and industrial research pursuits, and which adds costly delays to therapeutic development. The foundation's activities extend from exploratory biology to the identification and validation of therapeutic targets, and from drug discovery and development to clinical studies and trials.

This year, CHDI Foundation is organising its 15(th) annual Huntington's Disease Therapeutics Conference. A forum for drug discovery and development, the conference brings together colleagues in the field to share ideas and make connections in the pursuit of therapeutics for Huntington's disease.

For more information, please visit https://chdifoundation.org/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRAUWVARRRUUAAR

(END) Dow Jones Newswires

February 19, 2020 04:00 ET (09:00 GMT)